RNA Nanoparticles for Eye Conditions Causing Vision Loss
Intracellular RNA Nanoparticle Therapeutics to Treat Retinal Neovascularization
This research explores a new way to deliver medicine using tiny RNA nanoparticles to treat serious eye conditions like diabetic retinopathy, aiming for longer-lasting effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11109695 on NIH RePORTER |
What this research studies
Many people with diabetic retinopathy and similar eye conditions need frequent eye injections to prevent vision loss. These regular injections can be uncomfortable and carry risks like infection. This project is developing a new method using special RNA nanoparticles that could deliver medicine more effectively and stay in the eye longer. The goal is to reduce the number of injections needed, making treatment easier and safer for patients.
Who could benefit from this research
Good fit: This research is relevant for individuals living with or at risk of retinal neovascularization, such as those with proliferative diabetic retinopathy or diabetic macular edema.
Not a fit: Patients without retinal neovascularization or similar eye conditions would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this approach could lead to treatments that require fewer eye injections, potentially improving patient comfort and reducing treatment risks for conditions like diabetic retinopathy.
How similar studies have performed: While RNA interference therapies have seen recent advancements and FDA approvals, this specific nanoparticle delivery method for extending therapeutic efficacy in retinal neovascularization is a novel approach.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Freeman, William R. — University of California, San Diego
- Study coordinator: Freeman, William R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.